AstraZeneca partners with Oracle to use AI in clinical trials

On October 20, 2026, AstraZeneca partnered with Oracle to apply artificial intelligence, cloud computing, and real-world data to clinical research. The collaboration aims to overcome recruitment delays, improve patient matching, and monitor safety signals across cancer, respiratory, and rare diseases. Launching with an Abu Dhabi hypertension project alongside M42, the initiative supports AstraZeneca's drive to overcome industry bottlenecks and achieve $80 billion in annual revenue by 2030.

Using AI and data in clinical research

• ▪AstraZeneca and Oracle plan to combine drug development expertise with artificial intelligence and healthcare data to identify eligible patients for clinical trials and monitor safety signals
• ▪On October 20, 2026, AstraZeneca announced a collaboration with Oracle to leverage artificial intelligence, cloud, and healthcare data capabilities to refine clinical research

Initial disease focus and first project

• ▪The initial research focus of the AstraZeneca and Oracle partnership announced on October 20, 2026 includes cancer, cardiovascular, respiratory, immunology, and rare diseases, alongside potential early disease diagnosis support
• ▪The first project under the AstraZeneca and Oracle collaboration announced on October 20, 2026 will support hypertension research and care in Abu Dhabi in partnership with UAE-based healthcare company M42